Clinical Trial Results:
AN OPEN-LABEL PHASE 2A STUDY TO INVESTIGATE DRUG-DRUG INTERACTIONS BETWEEN AT1001 (MIGALASTAT HYDROCHLORIDE) AND AGALSIDASE IN SUBJECTS WITH FABRY DISEASE
Summary
|
|
EudraCT number |
2010-022709-16 |
Trial protocol |
BE GB |
Global completion date |
09 Oct 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v2(current) |
This version publication date |
22 Aug 2018
|
First version publication date |
15 Sep 2016
|
Other versions |
v1 |
Version creation reason |
|
Summary report(s) |
AT1001-013 CSR Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.